Coagulation status modulates murine hepatic fibrogenesis: Implications for the development of novel therapies

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 8, 2008, Pages 1336-1343

  Anstee, Quentin M ^a,d   Goldin, R D ^a   Wright, M ^b   Martinelli, A ^a   Cox, R ^c   Thursz, M R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c MRC MAMMALIAN GENETICS UNIT   (United Kingdom)

^d ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Anticoagulation; Factor V Leiden; Fibrosis; Hepatitis; Liver; PAR1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLOOD CLOTTING FACTOR 5 LEIDEN; CARBON TETRACHLORIDE; HYDROXYPROLINE; PROTEINASE ACTIVATED RECEPTOR 1; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CELL ACTIVATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; SEX DIFFERENCE; STELLATE CELL;

ACTINS; ANIMALS; ANTICOAGULANTS; CARBON TETRACHLORIDE; FACTOR V; GENE EXPRESSION; HYDROXYPROLINE; LIPID PEROXIDATION; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MICE; MICE, CONGENIC; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICE, TRANSGENIC; POINT MUTATION; WARFARIN;

EID: 47649093322     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03015.x     Document Type: Article

References (42)

1. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003; 38(Suppl. 1): S38-53.
2. Northup PG, Sundaram V, Fallon MB, Reddy KR, Balogun RA, Sanyal AJ, Anstee QM, Hoffman MR, Ikura Y, Caldwell SH. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost 2007; 6: 2-9.
3. Levy GA, MacPhee PJ, Fung LS, Fisher MM, Rappaport AM. The effect of mouse hepatitis virus infection on the microcirculation of the liver. Hepatology 1983; 3: 964-73.
4. MacPhee PJ, Schmidt EE, Keown PA, Groom AC. Microcirculatory changes in livers of mice infected with murine hepatitis virus. Evidence from microcorrosion casts and measurements of red cell velocity. Microvasc Res 1988; 36: 140-9.
5. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-47.
6. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology 1995; 21: 1232-7.
7. Wright M, Goldin R, Hellier S, Knapp S, Frodsham A, Hennig B, Hill A, Apple R, Cheng S, Thomas H, Thursz M. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003; 52: 1206-10.
8. Poujol-Robert A, Boelle PY, Poupon R, Robert A. Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C. Hepatology 2004; 39: 1174-5.
9. Papatheodoridis GV, Papakonstantinou E, Andrioti E, Cholongitas E, Petraki K, Kontopoulou I, Hadziyannis SJ. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 2003; 52: 404-9.
10. Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem 1983; 258: 163-8.
11. Luckow EA, Lyons DA, Ridgeway TM, Esmon CT, Laue TM. Interaction of clotting factor V heavy chain with prothrombin and prethrombin 1 and role of activated protein C in regulating this interaction: Analysis by analytical ultracentrifugation. Biochemistry 1989; 28: 2348-54.
12. Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, Brenner B, Eldor A, Seligsohn U. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997; 89: 397-402.
13. Tsukamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: A review. Semin Liver Dis 1990; 10: 56-65.
14. Cui J, Eitzman DT, Westrick RJ, Christie PD, Xu ZJ, Yang AY, Purkayastha AA, Yang TL, Metz AL, Gallagher KP, Tyson JA, Rosenberg RD, Ginsburg D. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood 2000; 96: 4222-6.
15. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, James Phillips M, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
16. Recknagel RO, Glende EA Jr, Dolak JA, Waller RL. Mechanisms of carbon tetrachloride toxicity. Pharmacol Ther 1989; 43: 139-54.
17. Skalli O, Ropraz P, Trzeciak A, Benzonana G, Gillessen D, Gabbiani G. A monoclonal antibody against alpha-smooth muscle actin: A new probe for smooth muscle differentiation. J Cell Biol 1986; 103: 2787-96.
18. ABI Biosystems Inc. User Bulletin #2 ABI PRISM 7700 Sequence Detection System. Applied Biosystems Inc, 1997 & 2001.
19. Toye AA, Moir L, Hugill A, Bentley L, Quarterman J, Mijat V, Hough T, Goldsworthy M, Haynes A, Hunter AJ, Browne M, Spurr N, Cox RD. A new mouse model of type 2 diabetes, produced by N-ethyl-nitrosourea mutagenesis, is the result of a missense mutation in the glucokinase gene. Diabetes 2004; 53: 1577-83.
20. Lee HS, Shun CT, Chiou LL, Chen CH, Huang GT, Sheu JC. Hydroxyproline content of needle biopsies as an objective measure of liver fibrosis: emphasis on sampling variability. J Gastroenterol Hepatol 2005; 20: 1109-14.
21. Bergman I, Loxley R. Lung tissue hydrolysates: Studies of the optimum conditions for the spectrophotometric determination of hydroxyproline. Analyst 1969; 94: 575-84.
22. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: Carbon tetrachloride as a toxicological model. Crit Rev Toxicol 2003; 33: 105-36.
23. Moore K, Roberts LJ. Measurement of lipid peroxidation. Free Radic Res 1998; 28: 659-71.
24. Xu Z, Westrick RJ, Shen YC, Eitzman DT. Pulmonary fibrosis is increased in mice carrying the factor V Leiden mutation following bleomycin injury. Thromb Haemost 2001; 85: 441-4.
25. de Giorgio-Miller A, Bottoms S, Laurent G, Carmeliet P, Herrick S. Fibrin-induced skin fibrosis in mice deficient in tissue plasminogen activator. Am J Pathol 2005; 167: 721-32.
26. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
27. Abdel-Salam OM, Baiuomy AR, Ameen A, Hassan NS. A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat. Pharmacol Res 2005; 51: 59-67.
28. Wanless IR, Belgiorno J, Huet PM. Hepatic sinusoidal fibrosis induced by cholesterol and stilbestrol in the rabbit: 1. Morphology and inhibition of fibrogenesis by dipyridamole. Hepatology 1996; 24: 855-64.
29. Howell DC, Johns RH, Lasky JA, Shan B, Scotton CJ, Laurent GJ, Chambers RC. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 2005; 166: 1353-65.
30. Gunther A, Lubke N, Ermert M, Schermuly RT, Weissmann N, Breithecker A, Markart P, Ruppert C, Quanz K, Ermert L, Grimminger F, Seeger W. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003; 168: 1358-65.
31. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, Sasaki H. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-82.
32. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
33. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 2001; 34: 730-9.
34. Itagaki T, Shimizu I, Cheng X, Yuan Y, Oshio A, Tamaki K, Fukuno H, Honda H, Okamura Y, Ito S. Opposing effects of oestradiol and progesterone on intracellular pathways and activation processes in the oxidative stress induced activation of cultured rat hepatic stellate cells. Gut 2005; 54: 1782-9.
35. Shimizu I. Impact of oestrogens on the progression of liver disease. Liver Int 2003; 23: 63-9.
36. Hague S, Oehler MK, MacKenzie IZ, Bicknell R, Rees MC. Protease activated receptor-1 is down regulated by levonorgestrel in endometrial stromal cells. Angiogenesis 2002; 5: 93-8.
37. Goulding C, O'brien C, Egan H, Hegarty JE, McDonald G, O'farrelly C, White B, Kelleher D, Norris S. The impact of inherited prothrombotic risk factors on individuals chronically infected with hepatitis C virus from a single source. J Viral Hepat 2007; 14: 255-9.
38. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350: 2558-63.
39. Marra F, DeFranco R, Grappone C, Milani S, Pinzani M, Pellegrini G, Laffi G, Gentilini P. Expression of the thrombin receptor in human liver: Up-regulation during acute and chronic injury. Hepatology 1998; 27: 462-71.
40. Marra F, Grandaliano G, Valente AJ, Abboud HE. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: Potential role in liver injury. Hepatology 1995; 22: 780-7.
41. Fiorucci S, Antonelli E, Distrutti E, Severino B, Fiorentina R, Baldoni M, Caliendo G, Santagada V, Morelli A, Cirino G. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology 2004; 39: 365-75.
42. Martinelli A, Knapp S, Anstee Q, Worku M, Tommasi A, Zucoloto S, Goldin R, Thursz M. Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis. J Gastroenterol Hepatol 2007; DOI: 10.1111/j.1440-1746.2007.05220.x.